SCHEMBL6524073

SCHEMBL6524073

CS(=O)(=O)c1ccccc1-c1ncco1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
BRD4 O60885 1/20 0.47
EDNRB P24530 2/20 0.45
EDNRA P25101 2/20 0.45
KMT2A Q03164 3/20 0.43
POLB P06746 1/20 0.43
MEN1 O00255 2/20 0.42
LMNA P02545 1/20 0.42
CTSG P08311 3/20 0.40
KLK7 P49862 3/20 0.40
KLK14 Q9P0G3 3/20 0.40
KLK5 Q9Y337 3/20 0.40
PRSS1 P07477 1/20 0.40
HSD11B1 P28845 1/20 0.40
HPGDS O60760 1/20 0.39
CTRC Q99895 1/20 0.39
ATR Q13535 1/20 0.39
ALOX5AP P20292 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6026444 0.83 BRD4 (0.43) BRD4EDNRBEDNRAHPGDSALOX5AP
SCHEMBL10849784 0.82 BRD4 (0.42) BRD4EDNRBEDNRAHPGDSLTA4H
SCHEMBL1919495 0.78 HPGDS (0.52) BRD4EDNRBEDNRAHPGDSLTA4H
SCHEMBL7408116 0.78 BRD4 (0.41) BRD4EDNRBEDNRAHPGDSALOX5AP
SCHEMBL14600782 0.76 ADRA1D (0.46) RAB9ABRD4EDNRBEDNRAALOX5AP
SCHEMBL5408419 0.76 ALDH1A1 (0.48) KDM4EALDH1A1BRD4EDNRBEDNRA
SCHEMBL7402494 0.73 EDNRB (0.41) BRD4EDNRBEDNRAALOX5APFEN1
SCHEMBL3042288 0.73 BRD4 (0.49) ALDH1A1BRD4EDNRBEDNRAHPGDS
SCHEMBL5352440 0.73 EDNRA (0.50) RAB9AKDM4EALDH1A1BRD4EDNRB
SCHEMBL3031254 0.73 RAB9A (0.53) RAB9AKDM4EALDH1A1BRD4HPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1435956-A2 THERAPEUTIC COMBINATIONS FOR CARDIOVASCULAR AND INFLAMMATORY INDICATIONS Pharmacia Corporation (US) 2004-07-14 EP claimed
WO-2002078626-A2 THERAPEUTIC COMBINATIONS FOR CARDIOVASCULAR AND INFLAMMATORY INDICATIONS PHARMACIA CORPORATION (US) 2002-10-10 WO claimed
EP-0699192-A1 SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-03-06 EP claimed
WO-1994027980-A1 SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1994-12-08 WO claimed
WO-2005009340-A2 METHOD FOR THE TREATMENT OR PREVENTION OF RESPIRATORY DISORDERS WITH A CYCLOOXYGENASE-2 INHIBITOR IN COMBINATION WITH A MUSCARINIC RECEPTOR ANTAGONIST AND COMPOSITIONS THEREWITH PHARMACIA CORPORATION (US) 2005-02-03 WO disclosed